Unilife Announces Clinical Supply Agreement With Novartis
Unilife recently announced an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with one of Novartis’ targeted early stage pipeline drugs.
Under this agreement, Unilife will supply Novartis with a customized delivery device, consisting of syringe, needle, tubing, controller, and pump, to enable administration of a novel investigational Novartis drug into a targeted organ in clinical trials. Unilife has granted Novartis an option for exclusivity under this agreement.
The program to supply customized products for clinical use with Novartis drug candidates is the next phase in a development collaboration between the parties that was commenced in 2011, and continues to progress successfully. Under this agreement, Unilife will generate revenue on the basis of the clinical product supplies and activities involved in clinical development.
“I am pleased with our success to date in being an effective collaborator with Novartis,” said Mr. Alan Shortall, Chief Executive of Unilife. “This is another example of Unilife addressing the unmet needs of pharmaceutical companies to deliver advanced drugs in their pipelines. I am excited to supply Novartis with a differentiated game-changing device that provides alternative options for drug delivery.”
For commercial purposes and due to confidentiality clauses in the agreement, additional terms of the agreement, are to remain confidential at this time.
Unilife Corporation is a US-based developer and commercial supplier of injectable drug delivery systems. Unilife’s broad portfolio includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems, and novel devices. For more information, visit www.unilife.com.
Total Page Views: 1257
